Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000622670 | SCV000740728 | pathogenic | Inborn genetic diseases | 2014-09-08 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003401095 | SCV004112796 | pathogenic | UBE3A-related disorder | 2023-03-08 | criteria provided, single submitter | clinical testing | The UBE3A c.1811_1812delGT variant is predicted to result in a frameshift and premature protein termination (p.Cys604Tyrfs*23). This variant has been reported as pathogenic in individuals with neurological and epilepsy phenotypes. In at least one study, the variant was reported to occur de novo (Table S3, Helbig et al. 2016. PubMed ID: 26795593; Ganapathy et al. 2019. PubMed ID: 31069529). Frameshift variants upstream and downstream of this position have also been reported as pathogenic in individuals with Angelman syndrome phenotypes (HGMD, Human Gene Mutation Database). To our knowledge, this variant has not been reported in the literature or in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Taken together, this variant is interpreted as pathogenic. |
Clinical Molecular Genetics Laboratory, |
RCV000202543 | SCV000257506 | pathogenic | Angelman syndrome | 2008-05-16 | no assertion criteria provided | clinical testing |